ClinicalTrials.gg
CompletedNCT00507234Updated Nov 11, 2010

Study in Subjects Greater Than 40 Years of Age With COPD

A Phase 3 interventional study of formoterol fumarate inhalation solution in Chronic Obstructive Pulmonary Disease, sponsored by Dey. Completed at 19 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-11-11.

Sponsored by Dey (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Viatris Inc..

Enrollment
13th of 26
128 · median 128
Started
2007
with 1 other
Phase 3
12 of 26
none open now
Registered
9th of 26
by date

Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc., this one is the 13th largest by enrollment, is one of 2 that started in 2007, is one of 12 in phase 3, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc. is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc. as a file.
02

Study summary

This is a multicenter, Phase IIIb, randomized, double-blind, active-controlled, parallel-group, comparative study.

The objectives of this study are:

  1. To compare the efficacy of tiotropium 18 mcg once daily plus Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg twice daily to tiotropium 18 mcg once daily.
  2. To obtain safety data on the use of tiotropium 18 mcg once daily plus FFIS 20 mcg twice daily compared to tiotropium 18 mcg once daily.
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical diagnosis of
  • Current or prior history of cigarette smoking

Exclusion criteria

Exclusion Criteria:

  • Medical diagnosis of asthma
  • Significant condition or disease other than
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (actual)

Interventions

  • Drugformoterol fumarate inhalation solution
06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint will be the standardized area under the curve for FEV1 (FEV1 AUC0-3) over the 3-hour assessment period at End Study (Week 6/ET).

    Time frame: 6 weeks

07

Study locations

19 sites
  • Clinical Research Site
    Mobile, Alabama 36695, United States
  • Clinical Research Site
    Phoenix, Arizona 85006, United States
  • Clinical Research Site
    DeLand, Florida 32720, United States
  • Clinical Research Site
    Atlanta, Georgia 30330, United States
  • Clinical Research Site
    Livonia, Michigan 48152, United States
  • Clinical Research Site
    St. Charles, Missouri 63301, United States
  • Clinical Research Site
    St. Louis, Missouri 63141, United States
  • Clinical Research Site
    Albany, New York 12205, United States
  • Clinical Research Site
    North Syracuse, New York 13212, United States
  • Clinical Research Site
    Williamsville, New York 14221, United States
  • Clinical Research Site
    Toledo, Ohio 45560, United States
  • Clinical Research Site
    Medford, Oregon 97504, United States
  • Clinical Research Site
    Portland, Oregon 97213, United States
  • Clinical Research Site
    Greenville, South Carolina 29615, United States
  • Clinical Research Site
    Spartanburg, South Carolina 29303, United States
  • Clinical Research Site
    San Antonio, Texas 78229, United States
  • Clinical Research Site
    Abingdon, Virginia 24210, United States
  • Clinical Research Site
    Richmond, Virginia 23225, United States
  • Clinical Research Site
    Milwaukee, Wisconsin 53209, United States
08

References and documents

Publications

  • Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18;69(9):1205-16. doi: 10.2165/00003495-200969090-00005. PubMed 19537837 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Oct 2007 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2007
First posted
Jul 26, 2007
Start
Mar 2007
Primary completionActual
Oct 2007
CompletionActual
Apr 2008
Last update
Nov 11, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00507234
Lead sponsor
Dey
First posted
Jul 26, 2007
Start date
Mar 2007
Primary completion
Oct 2007
Completion
Apr 2008
Last update
Nov 11, 2010

Study contacts

Nicola A Hanania, MD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion